Nektar Therapeutics (NKTR) Stock Price & Analysis
NKTR Stock Chart & Stats
- Day’s Range
- MXN 1,010.00 - MXN 1,010.00
- 52-Week Range
- MXN 693.50 - MXN 1,742.00
- Previous Close
- MXN 1,010.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 24.93B
- Enterprise Value
- MXN 1.76B
- Total Cash (Recent Filing)
- MXN 684.34M
- Total Debt (Recent Filing)
- MXN 135.93M
- Price to Earnings (P/E)
- ―
- Beta
- 0.35
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -38.87
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical Efficacy
Long-lasting efficacy and less frequent maintenance dosing could differentiate rezpegaldesleukin in dermatology, improving convenience and supporting physician adoption if Phase 3 confirms the results. The durability signals strengthen the commercial rationale across both atopic dermatitis and alopecia areata.
Late-Stage Pipeline Progress
Advancing into pivotal trials moves the lead program closer to potential regulatory filings and creates identifiable development milestones over the next several years. Progress in two large immune dermatology indications broadens the opportunity and can improve the value of the clinical pipeline.
Strong Liquidity Runway
The substantial cash balance gives Nektar resources to fund pivotal development and planned operating needs without an immediate financing requirement. Runway into Q3 2028 supports execution through important atopic dermatitis readouts, providing greater planning flexibility for a clinical-stage company.
Bears Say
Substantial Cash Burn
Nektar is consuming substantial cash while its programs remain pre-commercial, making continued financing capacity important to sustain development. Even with a strong current cash balance, persistent operating losses can reduce flexibility and increase the consequences of trial delays or higher development costs.
Contracting, Non-Product Revenue
The company lacks a broad recurring product-revenue base and currently depends heavily on collaboration or royalty income. Contracting and modest revenue provide limited support for the cost structure, leaving future financial strength dependent on successful development, approvals, and eventual commercialization.
Regulatory And Timing Risk
Nektar’s main value-creation milestones remain several years away and depend on positive Phase 3 outcomes, regulatory interactions, and timely execution. Delays, unfavorable data, or adoption challenges could extend losses and require additional capital before rezpegaldesleukin generates product revenue.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
What is Nektar Therapeutics’s market cap?
When is Nektar Therapeutics’s upcoming earnings report date?
How were Nektar Therapeutics’s earnings last quarter?
Is Nektar Therapeutics overvalued?
Does Nektar Therapeutics pay dividends?
What is Nektar Therapeutics’s EPS estimate?
How many shares outstanding does Nektar Therapeutics have?
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Nektar Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Nektar Therapeutics Stock Smart Score
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Howard W. Robin
- Employees
- 63
- Website
- www.nektar.com
- Address
- 455 Mission Bay Boulevard South, San Francisco, CA, 94158, US
Nektar Therapeutics (NKTR) Earnings & Revenues
NKTR Earnings Call
Earnings Call SentimentPositive
The call contained multiple substantial positive developments: initiation of the global Phase 3 program in atopic dermatitis, FDA-aligned registrational design for alopecia areata, strong Phase 2b signals (efficacy, durability, favorable safety), robust cash balance after a $350M offering, and encouraging market research supporting commercial potential. Offsetting these positives are expected higher R&D and G&A spend, a meaningful quarterly net loss, modest near-term revenue largely from non-cash royalties, a cash runway that covers key mid-2028 readouts but leaves limited buffer for delays, and an ongoing litigation matter. On balance the strategic, clinical, and financial highlights outweigh the risks described on the call.
View all MX:NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 1 | 13 |
| Technical Analysis | 1 | 0 | 3 |
| Moving Averages | 1 | 1 | 10 |